MIA joins Sydney Health Partners
MIA has joined Sydney Health Partners, with a shared focus on more rapidly translating research evidence into patient benefit.
MIA has joined Sydney Health Partners, with a shared focus on more rapidly translating research evidence into patient benefit.
A promising young MIA researcher is conferred with University of Sydney PhD.
Developing a screening technique to provide clinicians with rationale for selecting a drug treatment regime.
Understanding the genes involved in the development of early brain metastases.
Identifying genes involved in all melanoma sub-types, to determine the most effective treatment.
Using whole genome sequencing technologies to identify the genetic mutations that cause melanoma, so treatment can be personalised.
Identifying genes which determine response to immunotherapy, and then determining the signalling pathways these genes are affecting.
MIA is experiencing great success with multi-discipline trials in the neo-adjuvant and adjuvant settings.
Jana Pittman and Melinda Gainsford-Taylor back our Game On Mole campaign, in support of their much loved coach.
Research to determine the value of providing patients with the services of a support clinic following dissection surgery.